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Summary
In accordance with the link between increased GH
and IGF-I secretion and cancer, we found that ho-
mozygous patients with Laron syndrome (severe
GH insensitivity) and low to undetectable serum
IGF-I are protected from developing cancer even if
treated with IGF-I to enhance linear growth.
KEY WORDS: Laron syndrome; GH receptor; IGF-I
and cancer; GH insensitivity; cancer.
Introduction
Cancer cells are characterized by their capacity for
self-sufficient proliferation, refractoriness to growth in-
hibitory signals, resistance to apoptosis and capacity
to recruit angiogenesis (1). The causes of cancer in-
clude genetic predisposition, gene-environment inter-
actions and infections agents. Among the risk factors
are hormones including pituitary growth hormone (GH)
and insulin like growth factor I (IGF-I) (2-4). In 1966 we
described a new disease resembling congenital isolat-
ed GH deficiency (c1GHD) (5) but which surprisingly
was found to be characterized by high serum levels of
GH and low to undetectable levels of IGF-I (6). The pa-
tients originated from the Middle East and most be-
longed to consanguineous families (7). Subsequently
more patients were diagnosed in various parts of the
world (5), and the disease was coined by William
Daughaday Laron type dwarfism, and changed subse-
quently to Laron syndrome (LS, OMIM#262500). In
1983 we showed that liver membranes of LS patients
could not bind 125I-hGH explaining the etiology of this
disease as insensitivity (resistance) to GH (8), subse-
quently we and others demonstrated that the resist-
ance to GH was due to deletions (9) or mutations in the
hGH receptor (5, 10).
Aim of Study
Having a population with an inability to generate IGF-I
we considered it to be the right model to test, the rela-
tionship between IGF-I deficiency and cancer.
We hypothesized that if indeed GH/IGF-I promotes ma-
lignancy: patients with congenital IGF-I deficiency as
exemplified by Laron syndrome should be cancer free. 
Subjects and Methods
To test this hypothesis we analyzed the medical charts
of our 68 LS patients, sent a questionnaire to medical
clinics known to follow patients with LS and screened
the medical literature for published patients (11-13).
We were able to collect data on 234 patients with LS,
adding recently 4 new patients to those included in the
report by Steuerman et al. (14). Dr Guevara-Aguirre
who follows 99 patients in Ecuador expressed the wish
to analyze their patients separately (personal commu-
nication).
It is assumed that both groups together amounting to
334 patients represent about 2/3 of all Laron Syndrome
patients in the world. Sixty-four patients in the pediatric
age group had been treated with IGF-I for many years;
so were 5 adult patients but only for one year (5, 7).
We were also able to obtain data on 339 first and sec-
ond degree relatives.  
Statistics
The collected data were analyzed using the BMDP sta-
tistical software (14). One-way and two-way ANOVA
were used to analyzed continuous variables (age) and
as for discrete variables (diagnosis/type of malignan-
cy). X2 test and Fisher’s exact test were used. A P val-
ue <0.05 was considered statistically significant.
Results
The study was performed in two stages: the first part per-
formed during the years 2004-2006, led to the announce-
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ment of the preliminary and exciting results in 2005 at a
cancer meeting in Taormina (15) namely that none of the
LS patients had developed cancer their age ranging from
3-78 years with a mean age of 32.3 years in our cohort
and 16 years in the US and European one. These find-
ings in 169 patients with Laron syndrome and 250 rela-
tives were published in 2007 (16). We continued to col-
lect data to ascertain these findings and published the
second stage early in the year 2011 (14). The study was
updated until August 2013. Table 1, which also includes
the findings of the Ecuadorian groups (17).
It is evident that none of the homozygous LS patients,
many of them adults, even old, had developed any ma-
lignancy whereas their heterozygote 1st degree rela-
tives have.
Discussion
Our findings that homozygous patients with Laron syn-
drome are protected from developing cancer have
been confirmed by Guevara-Aguirre et al. (17) who
surveyed 99 patients with LS in Ecuador. One of their
LS patients who developed ovarian carcinoma was a
double heterozygote. 
The mechanism which protects the patients with Laron
syndrome is so far undetermined. Their 1st degree het-
erozygote family members (parents and siblings) who
are not protected from cancer do not resemble pheno-
typically LS patients (6, 7). The cause must be related
to the fact that the heterozygote subjects produce ac-
tive growth hormone and IGF-I. The conclusion is that
only complete congenital absence of IGF-I induces a
cancer protective mechanism.
We (18) and probably others (17) are taking on the
challenge to solve the riddle which should lead not on-
ly to a better understanding of the link between IGF-I
and cancer but hopefully to improved and novel treat-
ment.
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